ATCC? Number:VR-1508?
Classification: Poxviridae, Orthopoxvirus
Agent: Vaccinia virus
Strain: Modified vaccinia virus Ankara (MVA)
Original Source: Attenuated vaccine strain (MVA was isolated by serial passage of CVA (Ankara) strain in chick embryo fibroblasts (CEF) in the laboratory of Professor Anton Mayr and then given to the National Institutes of Health, where it was plaque purified three times in CEF cells. VR-1508 was established by passage of the CEF-derived seed from the NIH in BHK-21 cells (ATCCCCL-10), an alternate host, at the ATCC.)
Depositors: B Moss, LS Wyatt
History: ATCC<<--B Moss, LS Wyatt<<--A. Mayr
Biosafety Level:2
Shipped: frozen
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Incubation : Duration: 3-7 days at 37C
Effect : Yes, Cytopathic effect: Rounding and death of infected cells
Store at : -70.0°C or colder (or colder)
Comments : Does not replicate in human cells or the majority of mammalian cells. This is a highly attenuated strain of vaccinia that some experts feel can be handled safely by trained personnel without the need for vaccination. This strain has been sequenced. [112444] GENBANK U94848, Vaccinia virus strain Ankara, complete genomic sequence Preparations of this strain are very stable and typically survive several days at room temperature. [112444]